Chicago biotech Emalex says it cleared a Phase 3 for Tourette syndrome, will seek FDA approval

Kyle LaHucik

Senior Reporter

Emalex Biosciences said its daily oral tablet helped reduce relapses for children and adults with Tourette syndrome in a Phase 3 study, and now plans …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Chicago biotech Emalex says it cleared a Phase 3 for Tourette syndrome, will seek FDA approval

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Sanofi to pay $125M upfront for two immunology drugs from little-known biotech

Exclusive: VelaVigo inks another US biotech deal as China drug development scene booms

US drugs rely heavily on ingredients made overseas, new report shows

Eli Lilly reports first Phase 3 data for oral GLP-1, posting a win in diabetes

Netherlands pours $1.5B into biotech in pursuit of global leadership ambitions

New York-based partnership sets the standard for expanding clinical trial access for underserved and diverse ...

Chica­go biotech Emalex says it cleared a Phase 3 for Tourette syn­drome, will seek FDA ap­proval

Senior Reporter

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Chicago biotech Emalex says it cleared a Phase 3 for Tourette syndrome, will seek FDA approval